CEFPROZIL POWDER FOR ORAL SUSPENSION POWDER FOR SUSPENSION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

CEFPROZIL (CEFPROZIL MONOHYDRATE)

Beschikbaar vanaf:

RANBAXY PHARMACEUTICALS CANADA INC.

ATC-code:

J01DC10

INN (Algemene Internationale Benaming):

CEFPROZIL

Dosering:

250MG

farmaceutische vorm:

POWDER FOR SUSPENSION

Samenstelling:

CEFPROZIL (CEFPROZIL MONOHYDRATE) 250MG

Toedieningsweg:

ORAL

Eenheden in pakket:

50/75/100ML

Prescription-type:

Prescription

Therapeutisch gebied:

SECOND GENERATION CEPHALOSPORINS

Product samenvatting:

Active ingredient group (AIG) number: 0127613004; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2009-08-20

Productkenmerken

PRODUCT MONOGRAPH
PR
CEFPROZIL POWDER FOR ORAL SUSPENSION
CEFPROZIL POWDER FOR ORAL SUSPENSION USP
(250 MG/5 ML OF CEFPROZIL AS CEFPROZIL MONOHYDRATE, WHEN
RECONSTITUTED)
USP
ANTIBIOTIC
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive,
Brampton, Ontario
L6T 1C1
Date of Revision:
October 9, 2019
Submission Control No.: 230902
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................ 4
SUMMARY PRODUCT INFORMATION
.................................................................................
4
INDICATIONS AND CLINICAL USE
.......................................................................................
4
CONTRAINDICATIONS
............................................................................................................
5
WARNINGS AND PRECAUTIONS
...........................................................................................
5
ADVERSE REACTIONS
.............................................................................................................
7
DRUG INTERACTIONS
.............................................................................................................
9
DOSAGE AND ADMINISTRATION
.........................................................................................
9
OVERDOSAGE
.........................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
11
STORAGE AND STABILITY
...................................................................................................
12
STORAGE OF RECONSTITUTED SUSPENSION
................................................................. 12
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................................... 13
PART II: SCIENTIFIC INFORMATION
.....................................................................................
14
PHARMACEUTICAL INFORMATION
...................